CliffBio
small molecule

RAMIPRIL

RAMIPRIL

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameRAMIPRIL
Active ingredientRAMIPRIL
Strength5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2008
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RAMIPRIL patent cliff — loss of exclusivity — | CliffBio